AIM ImmunoTech
Dirigeants
Voir l'organigramme avec ses 8 principaux dirigeants
Biographies les plus recherchées chez AIM ImmunoTech
- Thomas Equels, Executive Vice Chairman, Chief Executive Officer a...
- Nancy Bryan, Director
- William Mitchell, Chairman of the Board
Créer une alerte
pour suivre les mouvements de dirigeants chez AIM ImmunoTech.
Biotechnologie
AIM ImmunoTech a 2 292 concurrents dont Lonza (Suisse), Eurofins (Luxembourg) et Deepull (Espagne).
Actualités en fusion/acquisition en Biotechnologie.
- Amber Therapeutics vient d'annoncer une levée de fonds de 100 millions de dollars. (publié le 10 juin 2024).
- Restor3d vient d'annoncer une levée de fonds de 70 millions de dollars. (publié le 8 juin 2024).
- Vilya vient d'annoncer une levée de fonds de 71 millions de dollars. (publié le 6 juin 2024).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par AIM ImmunoTech
- Press Releases | AIM Immunotech
- AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise - AIM ImmunoTech Inc.
- AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast - AIM ImmunoTech Inc.
- AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease - AIM ImmunoTech Inc.
- AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease - AIM ImmunoTech Inc.
- AIM ImmunoTech Issues Letter to Stockholders - AIM ImmunoTech Inc.
- AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients - AIM ImmunoTech Inc.
- AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, "Long Covid: What Will It Take To Accelerate Therapeutic Progress?" - AIM ImmunoTech Inc.
- AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center - AIM ImmunoTech Inc.
- AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention - AIM ImmunoTech Inc.
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de AIM ImmunoTech
- AIM ImmunoTech sur Wikipédia, Google News & Yahoo Finance en 1-click
- AIM ImmunoTech sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Thomas Equels 
Appelez AIM ImmunoTech au +1 212...
